Drugs / IMP3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00682227 | Aug 2006 → Dec 2008 | esophageal squamous cell carcinoma | University of Yamanashi | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00995358 | Nov 2008 → Oct 2010 | esophageal squamous cell carcinoma | University of Yamanashi | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMP-3 | “Since a phase I clinical trial using three HLA-A24-binding peptides from TTK protein kinase (TTK), lymphocyte antigen-6 complex locus K (LY6K), and insulin-like growth...” PMID 22776426 ↗ Jul 2012 |
| Target | IMP3 | “We previously identified three novel HLA-A24-restricted epitope peptides, which were derived from three cancer-testis antigens, TTK protein kinase (TTK), lymphocyte antigen 6...” PMID 19459850 ↗ May 2009 |